Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study

BACKGROUND: With advancement in the treatment options of rheumatoid arthritis (RA), optimising the outcomes of difficult-to-treat patients has become increasingly important in clinical practice. In particular, insensitivity to first-line biologic disease-modifying anti-rheumatic drugs (bDMARD) is be...

Descripción completa

Detalles Bibliográficos
Autores principales: Ochi, Sae, Saito, Kazuyoshi, Mizoguchi, Fumitaka, Kato, Shigeaki, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057565/
https://www.ncbi.nlm.nih.gov/pubmed/32131890
http://dx.doi.org/10.1186/s13075-020-2122-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057565/
https://www.ncbi.nlm.nih.gov/pubmed/32131890
http://dx.doi.org/10.1186/s13075-020-2122-5

Ejemplares similares